Article info

Download PDFPDF
Randomised controlled trial
In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates

Authors

  1. Correspondence to: Professor Michael LeFevre, Department of Family and Community Medicine, University of Missouri, M224 Health Sciences Center, Columbia, MO 65212, USA; lefevrem{at}health.missouri.edu
View Full Text

Citation

LeFevre M
In individuals at intermediate risk for cardiovascular disease, treatment with rosuvastatin but not candesartan plus hydrochlorothiazide lowers cardiovascular disease event rates

Publication history

  • First published October 6, 2016.
Online issue publication 
November 23, 2016

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.